
An Issuer Playbook for Navigating COVID-19


March 4, 2020



The increase of COVID-19 cases outside China has shocked markets



Number of countries with at least 1 case of COVID-19



12,000

10.000

8.000

6,000

4.000

Number of active confirmed cases of COVID-19¹

China ex. Hubei


----Global ex. China

212312020

212612020

212912020

31312020



Source: J.P. Morgan's DataQuery, Bloomberg, World Health Organization, National Health Commission of PRC


Note: Data as of 03/03/2020; ¹ Active confirmed cases = total confirmed cases - total deceased / recovered; ² Represents price return over the period; ³ Investment grade refers to the JULI index, High yield refers to the J.P. Morgan Global HY Index

It remains to be seen whether markets are appropriately pricing virus risk



S&P 500 P/E ratios have declined rapidly, but the impact to earnings remains uncertain


In contrast to equity markets, credit spreads have widened less than what may be implied by equity volatility



Source: Bloomberg


Note: Data as of 03/03/2020; ¹ Represents data points over the last year (03/01/2019 – 03/03/2020); ² CDX IG CDSI generic 5-year credit spreads; ³ CDX IG CDSI generic 5-year credit spreads

Chinese markets recovered as coronavirus cases peaked; will the U.S. markets follow a similar pattern?



Daily infections in China ex Hubei and Chinese market performance


Daily infections globally ex China and U.S. market performance



It seems too early to know if the impacts of COVID-19 will be short-lived or ultimately have longer-lasting consequences, up to and including a recession

The market was already expecting the Fed to take action...


Probability of the number of Federal Funds Rate cuts for the 3/18/20 meeting



Implied recession probabilities have spiked

50% 44% 39% 36% 40% 23% 24% 30% 16% 20% 13% 12% %12% 12% 12% 10% 0% 217412020 21712020 21/8/2020 212012020 212412020 212512020 212812020 212712020 212812020 21/912020 212112020 31212020 3/3/2020

Probability of recession within 12 months based on S&P 500 and BBB spread



Key takeaways

- While central banks have begun to take action to blunt the economic impact of COVID-19, there may be little stimulus can do to remedy uncertainty
- Unlike other recent market moving events (e.g., trade), COVID-19 won't be swayed by market pressures
- While we hope for a quick resolution to COVID-19 uncertainty, firms should prepare for a more prolonged downturn to ensure financial resilience


J.P.Morgan

Source: J.P. Morgan's DataQuery, Bloomberg, Federal Reserve Bank of St. Louis Economic Research Note: Data as of 03/03/2020


Precedents may be informative, but uncertainty remains

Comparing COVID-19, SARS, and MERS

Number of confirmed cases




Fatality rate



Velocity of the virus

Number of days for the first 1,000 people to be infected



Comparing viral outbreaks

	COVID-19	SARS	MERS
Central bank actions	✓ ¹	\checkmark^2	✓ ³
Widespread travel restrictions	1	1	×
Number of countries affected	73+	29	27
Duration	?	~6 months	8+ years

Key takeaways

- While precedents exist, the exponential rise of COVID-19 is unlike severe viral outbreaks seen in the recent past
- SARS began in 2002, but was short lived
 - Spread rapidly, but still not as fast as COVID-19
 - Tapered off in around 6 months and ended in almost 8 months
- MERS began in 2012, but took much longer to spread
 - After 1 year, MERS only infected 108 people
 - Took 8 years for MERS to infect over 2,500 people

J.P.Morgan

Source: Reuters, World Health Organization, Center for Disease Control and Prevention; Note: COVID-10 refers to coronavirus disease, SARS refers to severe acute respiratory syndrome, and MERS refers to Middle East respiratory syndrome. Data as of 03/03/2020 for COVID-19, data as of latest available for SARS and MERS; ¹ U.S. Federal Reserve cut rates by 50 bps in response to coronavirus outbreak on 03/03/2020; ² Canada's central bank cut rates in response to the SARS outbreak; ³ South Korea's central bank cut rates in response to the MERS outbreak in 2015

5

- 1 What happens if the virus **continues to spread** to other areas of the world?
- 2) What impact will this have on suppliers, customers, and employees?
- 3) What happens if this precipitates a global recession?
 - What happens if **capital markets remain challenging** for a prolonged period of time?
- 5) What happens if **rates are cut and long term rates go even lower**?
- 6
- What happens if the **dollar gets stronger** as a safe haven?
- 7) What happens if the damage is more contained and there is a "v-shaped" recovery?


6

A playbook for navigating current volatility

- Firms should prioritize keeping their greatest assets their employees healthy and safe
- CFOs and finance teams should be proactive to ensure financial preparedness and stability during this time

	Preparation	Potential actions
Capital structure	 Revisit near- and medium-term capital market dependencies. What are contingency plans? Sensitize leverage metrics to account for different financial outcomes Anticipate regional cash flow shortfalls and funding needs in different jurisdictions 	 Opportunistically tap capital markets during windows of market stability to take advantage of historically low interest rates, term out CP, and/or near-term maturities? Reallocate capital from discretionary expenditures (e.g. share repurchases) to debt paydown?
Liquidity	 Assess the risk of near-term liquidity needs under downside scenarios Monitor access to commercial paper (if applicable) Evaluate downside case "bookends" that account for both a short-term shock as well as a longer-term downturn into recession 	 Engage with rating agencies to ensure that tapping sources of liquidity to leave on balance sheet doesn't result in ratings actions? Look for embedded gains in derivatives for a possible source of liquidity?
Risk management	 Evaluate hedging opportunities for rates, currencies, and commodities Consider pension implications of weak equity performance and low interest rates 	 Lock rates, FX, and commodity costs? Reduce pension funding to regulatory minimum to preserve cash flow?
Supply chain	 Assess the impact of recent events on vendors and suppliers Consider building inventory in cases where disruptions are anticipated 	 Extend financing / payable terms to more vulnerable suppliers? Seek payment term extensions from customers?
Capital allocation	 Contemplate opportunistic return of capital if capital structure / liquidity support it 	 Consider changing pace of share buybacks to either preserve flexibility or to be opportunistic? Evaluate investment opportunities at new valuation levels?

Risk management themes across asset classes



Call to action


- 1. Re-evaluate unhedged risks in current market backdrop
- 2. Determine risk tolerance levels
- 3. Seek internal approvals for risk management strategies

¹ Based on JPM Corporate Derivative execution only
 ² Based on JPM activity and public filings

8



Investment grade borrowing costs dropped to all-time lows despite the volatility





Borrowing costs have diverged in light of recent volatility, as IG credit risk premiums have not fully offset the move lower in UST yields

The recent hiatus in primary issuance is not unique relative to other periods of market volatility...



...with overall supply/demand dynamics supported by IG credit's status as a safe haven asset for investors






Coronavirus fears have weighed on leveraged finance markets


Strong leveraged finance technicals (only ~\$35bn in the fwd M&A calendar) will contest escalating fundamental concerns (coronavirus, US election) to drive market sentiment in and out of issuer's favor. It is increasingly important to stay nimble to take advantage of windows of opportunity as they present themselves

S&P 500: Valuations remain above long term averages, despite recent market sell-off




S&P 500 subsector price performance

U.S. equity issuance (\$bn)




Market volatility & trading volume, 2020YTD



Source: Bloomberg, Dealogic, FactSet as of 02/28/20 Note: Issuance data excludes offerings <\$50mm; ¹ Excludes bought offerings

S&P 500 NTM P/E multiples, 2019 - 2020YTD



This presentation was prepared exclusively for the benefit and internal use of the J.P. Morgan client to whom it is directly addressed and delivered (including such client's subsidiaries, the "Company") and does not carry any right of publication or disclosure, in whole or in part, to any other party. This presentation is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by J.P. Morgan. Neither this presentation nor any of its contents may be disclosed or used for any other purpose without the prior written consent of J.P. Morgan.

The information in this presentation reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. J.P. Morgan's opinions and estimates constitute J.P. Morgan's judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was otherwise reviewed by us.

This presentation is a product of J.P. Morgan's Investment Banking Group and not the Research Department and does not constitute investment advice or any offer to sell or any solicitation of any offer to buy any security or other investment.

J.P. Morgan is a party to the SEC Research Settlement and as such, is generally not permitted to utilize the firm's research capabilities in pitching for investment banking business. All views contained in this presentation are the views of J.P. Morgan's Investment Bank, not the Research Department. J.P. Morgan's policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a subject company as consideration or inducement for the receipt of business or for compensation. J.P. Morgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.jpmorgan.com/global/disclosures/interbank_offered_rates

JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.

J.P. Morgan is a marketing name for investment businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide. Securities, syndicated loan arranging, financial advisory, lending, derivatives and other investment banking and commercial banking activities are performed by a combination of J.P. Morgan Securities LLC, J.P. Morgan Securities plc, J.P. Morgan AG, JPMorgan Chase Bank, N.A. and the appropriately licensed subsidiaries and affiliates of JPMorgan Chase & Co. worldwide. J.P. Morgan deal team members may be employees of any of the foregoing entities. J.P. Morgan Securities plc is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. J.P. Morgan AG is authorized by the German Federal Financial Supervisory Authority (*BaFin*) and regulated by BaFin and the German Central Bank (*Deutsche Bundesbank*).

For information on any J.P. Morgan German legal entity see: https://www.jpmorgan.com/country/US/en/disclosures/legal-entity-information#germany.

For information on any other J.P. Morgan legal entity see: https://www.jpmorgan.com/country/GB/EN/disclosures/investment-bank-legal-entity-disclosures.

This presentation does not constitute a commitment by any J.P. Morgan entity to underwrite, subscribe for or place any securities or to extend or arrange credit or to provide any other services.

Copyright 2020 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A., organized under the laws of U.S.A. with limited liability.

